SCHEMBL10074225

SCHEMBL10074225

Nc1cccc2c1C(=O)N(C1CCC(=O)OC1=O)C2=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 12/20 0.61
CRBN Q96SW2 12/20 0.61
IKZF3 Q9UKT9 3/20 0.61
TNF P01375 2/20 0.61
IL1B P01584 2/20 0.61
IKZF1 Q13422 2/20 0.61
TBXA2R P21731 1/20 0.61
TMEM97 Q5BJF2 3/20 0.48
HTR2B P41595 2/20 0.48
HTR3E A5X5Y0 1/20 0.48
HTR3B O95264 1/20 0.48
HTR3A P46098 1/20 0.48
HTR3D Q70Z44 1/20 0.48
HTR3C Q8WXA8 1/20 0.48
HTR2A P28223 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
HSPA1A P0DMV8 1/20 0.42
PABPC1 P11940 1/20 0.42
ALDH1A1 P00352 1/20 0.40
CHRM2 P08172 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10074267 0.87 CRBN (0.58) DDB1CRBNIKZF3TNFIL1B
SCHEMBL14601082 0.85 DDB1 (0.44) DDB1CRBNIKZF3TNFIL1B
SCHEMBL410243 0.84 CRBN (0.55) DDB1CRBNIKZF3TNFIL1B
SCHEMBL442296 0.84 CRBN (0.55) DDB1CRBNIKZF3TNFIL1B
SCHEMBL410700 0.84 CRBN (0.55) DDB1CRBNIKZF3TNFIL1B
SCHEMBL7284377 0.84 CRBN (0.55) DDB1CRBNIKZF3TNFIL1B
SCHEMBL14377303 0.81 DDB1 (0.65) DDB1CRBNIKZF3TNFIL1B
SCHEMBL15930060 0.81 DDB1 (0.65) DDB1CRBNIKZF3TNFIL1B
SCHEMBL23575795 0.77 DDB1 (0.44) DDB1CRBNIKZF3TNFIL1B
SCHEMBL7850526 0.76 CRBN (0.62) DDB1CRBNIKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522899-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) 2016-12-20 US disclosed
US-9522899-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) 2016-12-20 US disclosed
US-20150284329-A1 Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-9085530-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-07-21 US disclosed
US-9085530-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-07-21 US disclosed
EP-2438053-B1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) 2013-09-11 EP disclosed
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2012-03-29 US disclosed
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284329-A1 Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS DDB1 2649/4885CRBN 4352/4885IKZF3 1195/4885
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof DHPS, QDPR, FDPS DDB1 2778/4885CRBN 4078/4885IKZF3 1593/4885
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS DDB1 2778/4885CRBN 4078/4885IKZF3 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.